Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focusing on cancer therapies, has announced a conference call and webcast scheduled for November 6th, 2024, at 2 PM PT / 5 PM ET. The call will discuss the company's third-quarter 2024 financial results and provide a pipeline update for the quarter ended September 30th, 2024.

Investors can join the call by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Online registration is also available. A live webcast and slide presentation will be accessible through the "Investors & Media" section of the Arcus Biosciences website. A replay of the webcast will be made available after the event.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6^th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended September 30^th, 2024.

Investors interested in listening to the conference call may do so by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. Participants may also register for the call online using the following link: https://www.netroadshow.com/events/login?show=4818aee3&confId=72838. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for patients with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241022900050/en/

Investor Inquiries

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

When will Arcus Biosciences (RCUS) release its Q3 2024 financial results?

Arcus Biosciences will discuss its Q3 2024 financial results during a conference call and webcast on November 6th, 2024, at 2 PM PT / 5 PM ET.

How can investors join Arcus Biosciences' (RCUS) Q3 2024 earnings call?

Investors can join by dialing +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 940081. They can also register online or access the webcast through the company's website.

What will be discussed in Arcus Biosciences' (RCUS) upcoming conference call?

The call will cover Arcus Biosciences' third-quarter 2024 financial results and provide a pipeline update for the quarter ended September 30th, 2024.

Where can I find the webcast for Arcus Biosciences' (RCUS) Q3 2024 earnings call?

The live webcast and accompanying slide presentation will be available in the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com.